In this issue:
RedirecTT-1: novel dual-targeted bispecific regimen for RRMM
AURIGA: daratumumab-lenalidomide maintenance improves MRD-negativity
Early daratumumab for smoldering MM delays progression
Teclistamab elicits high response rates
Promising early results for bivalent anti-GPRC5D bispecific forimtamig
Integration of clinical outcomes and molecular features in EMD
Del(17p) confers unfavourable outcomes
Dexamethasone dose reductions do not adversely impact outcomes
Infections remain a major threat to patients with MM
Please login below to download this issue (PDF)